What is the recommended management and treatment for a posterior wall myocardial infarction?

Management of Posterior Wall Myocardial Infarction

Posterior wall MI should be treated as a STEMI equivalent requiring immediate reperfusion therapy with primary PCI as the preferred strategy, or fibrinolysis if PCI cannot be performed within 120 minutes of first medical contact. 1

Diagnostic Considerations

Posterior wall MI presents unique diagnostic challenges that directly impact treatment decisions:

• Obtain a 15-lead ECG (standard 12-lead plus V7-V9) in all patients with chest pain and ST depression in V1-V3, as isolated posterior STEMI shows ST elevation only in posterior leads V7-V9 in many cases 2, 3
• ST depression in V1-V3 with tall R waves, upright T waves, and marked ST depression >2 mm are concerning findings that warrant posterior lead evaluation 3, 4
• The circumflex artery is the culprit vessel in the vast majority of isolated posterior MIs 3
• Posterior wall motion abnormalities appear on echocardiography in 97% of cases, with significant mitral regurgitation occurring in approximately 69% of patients 3

Immediate Reperfusion Strategy

Primary PCI (Preferred Approach)

Reperfusion therapy is indicated in all patients with symptoms of ischemia <12 hours duration and persistent ST-segment elevation (including isolated posterior lead elevation). 1

Antithrombotic regimen for primary PCI:

• Aspirin 162-325 mg loading dose (oral or IV if unable to swallow) immediately 1
• Potent P2Y12 inhibitor (ticagrelor or prasugrel preferred over clopidogrel) given before or at the time of PCI, continued for 12 months unless excessive bleeding risk 1
• Anticoagulation with either:
  • Bivalirudin 0.75 mg/kg IV bolus, then 1.75 mg/kg/h infusion (preferred in high bleeding risk) 1
  • Unfractionated heparin 70-100 U/kg bolus to achieve therapeutic ACT 1
  • Fondaparinux is contraindicated for primary PCI 1

Fibrinolytic Therapy (When PCI Delayed >120 Minutes)

If primary PCI cannot be performed within 120 minutes of first medical contact, fibrinolytic therapy should be administered within 12 hours of symptom onset in patients without contraindications, preferably in the pre-hospital setting. 1

Fibrinolysis regimen:

• Fibrin-specific agent (tenecteplase, alteplase, or reteplase) 1
• Aspirin 162-325 mg loading dose 1
• Clopidogrel 300 mg loading dose (≤75 years) or 75 mg (>75 years) 1
• Anticoagulation with enoxaparin IV followed by subcutaneous (preferred over UFH) or weight-adjusted UFH bolus and infusion, continued until revascularization or up to 8 days 1

Post-fibrinolysis management:

• Transfer to PCI-capable center immediately after fibrinolysis 1
• Angiography and PCI of infarct-related artery between 2-24 hours after successful fibrinolysis 1
• Rescue PCI immediately if fibrinolysis fails (<50% ST-segment resolution at 60-90 minutes) or with hemodynamic/electrical instability 1

Acute and Long-Term Medical Management

In-Hospital Phase

• Routine echocardiography to assess LV/RV function, detect mechanical complications (particularly papillary muscle rupture given high MR rates), and exclude LV thrombus 1, 5, 3
• ECG monitoring with defibrillator capacity immediately 1
• Avoid routine oxygen unless SaO2 <90% 1
• Emergency surgery consultation if severe mitral regurgitation develops, as papillary muscle rupture can complicate posterior MI 5, 3

Long-Term Therapy (Post-Discharge)

Antiplatelet therapy:

• Dual antiplatelet therapy (DAPT) with aspirin 75-100 mg plus ticagrelor or prasugrel (or clopidogrel if unavailable/contraindicated) for 12 months 1
• PPI added in patients at high GI bleeding risk 1

Cardioprotective medications:

• High-intensity statin started immediately and continued long-term, targeting LDL-C <1.8 mmol/L (70 mg/dL) or ≥50% reduction 1
• ACE inhibitor started within 24 hours in patients with heart failure, LV dysfunction (LVEF <40%), diabetes, or anterior infarct 1
• Beta-blocker (oral) in patients with heart failure and/or LVEF <40%; avoid IV beta-blockers in hypotension, acute heart failure, or AV block 1
• Mineralocorticoid receptor antagonist in patients with LVEF <40% and heart failure or diabetes who are already on ACE inhibitor/ARB 1

Cardiac Rehabilitation and Risk Modification

• Enrollment in cardiac rehabilitation program 1
• Smoking cessation with pharmacotherapy (nicotine replacement, varenicline, or bupropion) and behavioral support 1

Critical Pitfalls to Avoid

• Missing the diagnosis: Posterior MI may show only ST depression in V1-V3 on standard 12-lead ECG; always obtain posterior leads (V7-V9) when clinical suspicion exists 2, 3, 4
• Delaying reperfusion: Do not wait for posterior lead confirmation if clinical suspicion is high and PCI can be performed immediately 1
• Underestimating mechanical complications: The high rate of mitral regurgitation (69%) and risk of papillary muscle rupture mandates careful echocardiographic evaluation 5, 3
• Using fondaparinux for primary PCI: This is contraindicated and associated with harm 1